Synopsis
Synopsis
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apo Dimenhydrinate
2. Apo-dimenhydrinate
3. Aviomarin
4. Biodramina
5. Calm X
6. Calm-x
7. Cinfamar
8. Contramareo
9. Dimen Heumann
10. Dimen Lichtenstein
11. Dimetabs
12. Dinate
13. Diphenhydramine Theoclate
14. Dmh
15. Dramamine
16. Dramanate
17. Gravol
18. Heumann, Dimen
19. Lnopharm, Reisetabletten
20. Lichtenstein, Dimen
21. Marmine
22. Motion Aid
23. Motion-aid
24. Nausicalm
25. Reisegold
26. Reisetabletten Lnopharm
27. Reisetabletten Ratiopharm
28. Reisetabletten Stada
29. Reisetabletten-ratiopharm
30. Rodovan
31. Rubiemen
32. Stada, Reisetabletten
33. Superpep
34. Theoclate, Diphenhydramine
35. Travel Well
36. Triptone
37. Vertigo Vomex
38. Vertigo-vomex
39. Vomacur
40. Vomex A
41. Vomisin
42. Wehamine
1. 523-87-5
2. Dramamine
3. Chloranautine
4. Vomex A
5. Diphenhydrinate
6. Anautine
7. Travelin
8. Amosyt
9. Aviomarin
10. Gravol
11. Menhydrinate
12. Andramine
13. Antemin
14. Diamarin
15. Dimenest
16. Dimentabs
17. Dramalen
18. Dramamin
19. Dramarin
20. Dramilin
21. Eldodram
22. Gravinol
23. Hydrinate
24. Novamine
25. Permital
26. Supremal
27. Teodramin
28. Travelmin
29. Troversin
30. Xamamina
31. Dimate
32. Dramyl
33. Dromyl
34. Reise-engletten
35. Neo-navigan
36. Diphenhydramine Theoclate
37. Diphenhydramine 8-chlorotheophylline
38. Diphenhydramine 8-chlorotheophyllinate
39. Nsc 117855
40. Jb937per5c
41. O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate
42. Nsc-117855
43. 1h-purine-2,6-dione, 8-chloro-3,7-dihydro-1,3-dimethyl-, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethanamine (1:1)
44. 8-chloro-1,3-dimethyl-1h-purine-2,6(3h,7h)-dione Compound With 2-(benzhydryloxy)-n,n-dimethylethanamine (1:1)
45. (o-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
46. Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
47. N,n-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
48. 2-(diphenylmethoxy)-n,n-dimethylethylamine 8-chlorotheophyllinate
49. Beta-dimethylaminoethyl Benzhydryl Ether 1,3-dimethyl-8-chloroxanthine
50. 2-(benzhydryloxy)-n,n-dimethylethylamine Compd. With 8-chlorotheophylline
51. 8-chlorotheophylline, Compound With 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1)
52. Dimenhydrinat
53. Theohydramine
54. Dommanate
55. Lomarin
56. Reidamine
57. Removine
58. Emedyl
59. Faston
60. 2-benzhydryloxy-n,n-dimethylethanamine;8-chloro-1,3-dimethyl-7h-purine-2,6-dione
61. Novamin (van)
62. Gravinol (antiemetic)
63. Dimenidrinato [dcit]
64. Sr-05000001608
65. [o-benzhydryl(dimethylamino)ethanol] 8-chlorotheophyllinate
66. Dimenhydrinatum [inn-latin]
67. Dimenidrinato
68. Dimenhidrinato [inn-spanish]
69. Ccris 4798
70. Hsdb 3064
71. Dramamine (tn)
72. Nci-c60639
73. 2-(diphenylmethoxy)-n,n-dimethylethanamine And 8-chloro-1,3-dimethyl-3,9-dihydro-1h-purine-2,6-dione
74. Dimenhydrinate,(s)
75. Einecs 208-350-8
76. Mfcd00054265
77. Spectrum_000974
78. Prestwick3_000265
79. Spectrum2_000992
80. Spectrum3_000397
81. Spectrum4_000517
82. Spectrum5_000909
83. Dsstox_cid_5087
84. Unii-jb937per5c
85. Dimenhydrinate [mi]
86. Schembl5128
87. Dimenhydrinate [inn]
88. Dimenhydrinate [jan]
89. Dsstox_rid_77660
90. Dsstox_gsid_25087
91. Bspbio_000110
92. Bspbio_002213
93. Dimenhydrinate [hsdb]
94. Kbiogr_001093
95. Kbioss_001454
96. Dimenhydrinate [vandf]
97. Divk1c_000049
98. Spectrum1500251
99. Spbio_001083
100. Dimenhydrinate [mart.]
101. Bpbio1_000122
102. Dimenhydrinate [usp-rs]
103. Dimenhydrinate [who-dd]
104. Chembl1200406
105. Dtxsid9025087
106. Chebi:94848
107. Hms500c11
108. Kbio1_000049
109. Kbio2_001454
110. Kbio2_004022
111. Kbio2_006590
112. Kbio3_001433
113. Dimenhydrinate (jp17/usp/inn)
114. Ninds_000049
115. Hms1920g20
116. Hms2091o08
117. Hms2095f12
118. Hms3712f12
119. Pharmakon1600-01500251
120. 2-(benzhydryloxy)-n,n-dimethylethylamine 8-chlorotheophyllinate
121. Hy-b1215
122. Dimenhydrinate [ep Impurity]
123. Dimenhydrinate [orange Book]
124. Dimenhydrinate [usp:inn:ban:jan]
125. Tox21_200323
126. Ccg-40210
127. Dimenhydrinate [ep Monograph]
128. Nsc117855
129. Nsc756740
130. S4672
131. Dimenhydrinate [usp Monograph]
132. Dimenhydrinate For Peak Identification
133. Akos015896341
134. Ac-8241
135. Cs-4841
136. Db00985
137. Nsc-756740
138. 8-chlorotheophylline, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1)
139. Ethylamine 2-(diphenylmethoxy)-n,n-dimethyl-, Compd With 8-chlorotheophylline (1:1)
140. Ethylamine, 2-(diphenylmethoxy)-n, N-dimethyl-, Compd. With 8-chlorothiophylline (1:1)
141. Ethylamine, N,n-dimethyl-2-(diphenylmethoxy)-, Compd. With 8-chlorotheophylline
142. Idi1_000049
143. Theophylline, 8-chloro-, Compd With 2-(diphenylmethoxy)-n,n-dimethyethylamine (1:1)
144. Theophylline, 8-chloro-, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1)
145. Ncgc00021154-01
146. Ncgc00021154-02
147. Ncgc00021154-03
148. Ncgc00021154-04
149. Ncgc00021154-05
150. Ncgc00021154-06
151. Ncgc00021154-07
152. Ncgc00091928-01
153. Ncgc00091928-02
154. Ncgc00091928-03
155. Ncgc00257877-01
156. 1h-pyrine-2,6-dione, 8-chloro-3,7-dihydro-1,3-dimethyl-, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethanamine (1:1)
157. As-13166
158. Bd166163
159. Ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, Compd. With 8-chloro-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione (1:1)
160. Sbi-0051350.p003
161. Ab00053833
162. Ft-0625019
163. Ft-0696921
164. D00520
165. D82297
166. Wln: T56 Bm Dn Fnvnvj Cg F H &622
167. 523d875
168. Q420439
169. Sr-05000001608-1
170. Sr-05000001608-2
171. Brd-m98649031-001-01-1
172. Dimenhydrinate, European Pharmacopoeia (ep) Reference Standard
173. Dimenhydrinate, United States Pharmacopeia (usp) Reference Standard
174. Ethylamine 2-(diphenylmethoxy)-n, Compd. With 8-chlorotheophylline (1:1)
175. Theophylline, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1)
176. Dimenhydrinate For Peak Identification, European Pharmacopoeia (ep) Reference Standard
177. Dimenhydrinate, Pharmaceutical Secondary Standard; Certified Reference Material
178. Theophylline, Compd. With 2-(diphenylmethoxy)-n,n-(dimethylethyl)amine (1:1)
179. 1h-purine-2, 8-chloro-3,7-dihydro-1,3-dimethyl-, Compd. With 2-(diphenylmethoxy)-n,n-dimethylethanamine (1:1)
180. 8-chloro-1,3-dimethyl-1h-purine-2,6(3h,7h)-dione 2-(benzhydryloxy)-n,n-dimethylethanamine Salt
181. 8-chloro-1,3-dimethyl-1h-purine-2,6(3h,7h)-dionecompoundwith2-(benzhydryloxy)-n,n-dimethylethanamine(1:1)
| Molecular Weight | 470.0 g/mol |
|---|---|
| Molecular Formula | C24H28ClN5O3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 469.1880675 g/mol |
| Monoisotopic Mass | 469.1880675 g/mol |
| Topological Polar Surface Area | 81.8 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 509 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antiemetics; Histamine H1 Antagonists
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
ABILITY TO INHIBIT EFFECTS OF HISTAMINE ON CAPILLARY PERMEABILITY & ON VASCULAR, BRONCHIAL, & MANY OTHER TYPES OF SMOOTH MUSCLE IS PROPERTY THAT CHARACTERIZES H1 ANTAGONISTS & THAT PROVIDES BASIS FOR THEIR PREVALENT CLINICAL USE... /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 603
"FLARE" COMPONENT OF TRIPLE RESPONSE & ITCHING CAUSED BY INTRADERMAL INJECTION OF HISTAMINE... H1-BLOCKING DRUGS SUPPRESS BOTH. ...HAVE LOCAL ANESTHETIC PROPERTIES... H1-BLOCKING DRUGS SELECTIVELY SUPPRESS STIMULANT EFFECT OF HISTAMINE ON ADRENAL CHROMAFFIN CELLS.../&/ AUTONOMIC GANGLION CELLS. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 605
...EFFICACY...IN COUNTERING HYPERSENSITIVITY REACTIONS WILL VARY, DEPENDING ON DEG TO WHICH SYMPTOMS ARE DUE TO HISTAMINE. ...IN MAN...SOME PHENOMENA, INCL EDEMA FORMATION & ITCH, ARE FAIRLY WELL CONTROLLED; OTHERS, SUCH AS HYPOTENSION ARE LESS SO; & BRONCHOCONSTRICTION...LITTLE IF AT ALL. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 605
For more Therapeutic Uses (Complete) data for DIMENHYDRINATE (12 total), please visit the HSDB record page.
SEE ANTIHISTAMINICS. CONSIDERABLE MARGIN OF SAFETY SEPARATES THERAPEUTIC DOSE FROM USUAL LETHAL ONE. HOWEVER, BECAUSE CONVULSANT DOSE LIES NEAR LETHAL DOSE, CONVULSIONS INDICATE POOR PROGNOSIS. ADULTS HAVE SURVIVED SINGLE DOSES OF 2.5-5.0 G. CHILDREN...30-60 MG/KG HAS PRODUCED...POISONINGS. /ANTIHISTAMINICS/
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-231
IN THERAPEUTIC DOSES, ALL H1 ANTAGONISTS ELICIT SIDE EFFECTS. ...RARELY SERIOUS & OFTEN DISAPPEAR...SOMETIMES...DRUG MUST BE WITHDRAWN. SOME DIFFERENCE...WITH DIFFERENT PREPN IS DISCERNIBLE...MARKED VARIATION IN RESPONSES OF INDIVIDUAL SUBJECTS... /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 607
...ANTICHOLINERGIC ACTIVITY, WHICH ACCOUNTS FOR DRYNESS OF MOUTH...&... DIFFICULTY IN MICTURATION & IMPOTENCE. SOME INTENSIFY RESPONSES TO NOREPINEPHRINE OR STIMULATION OF ADRENERGIC NERVES & INHIBIT RESPONSES TO TYRAMINE... RAPID IV INJECTION OF H1 ANTAGONISTS CAUSES TRANSIENT FALL IN BLOOD PRESSURE... /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 606
H1 ANTAGONISTS CAN BOTH STIMULATE & DEPRESS CNS. ...CENTRAL EXCITATION IS STRIKING FEATURE OF POISONING WITH ANTIHISTAMINES & CAN RESULT IN CONVULSIONS, PARTICULARLY IN INFANTS. CENTRAL DEPRESSION...IS USUAL ACCOMPANIMENT OF THERAPEUTIC DOSES. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 606
PERSONS TAKING ANTIHISTAMINES SHOULD BE ALERTED TO THEIR SEDATIVE EFFECTS & SHOULD BE CAUTIONED NOT TO DRIVE AN AUTOMOBILE, FLY AN AIRPLANE, OR OPERATE HAZARDOUS MACHINERY... /ANTIHISTAMINES/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1057
Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. It has a short duration of action of 4-8 hours. Patients should be counselled regarding pronounced drowsiness, avoiding alcohol and other sedatives, and exercising caution when operating a motor vehicle or heavy machinery.
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AA - Aminoalkyl ethers
R06AA11 - Dimenhydrinate
Absorption
A 50 mg oral film coated tablet reaches a Cmax of 72.6 ng/mL with a Tmax of 2.7 hours. A 100 mg suppository reaches a Cmax of 112.2 ng/mL with a Tmax of 5.3 hours.
Route of Elimination
Dimenhydrinate is predominantly eliminated in the urine. 1-3% of the dissociated diphenhydramine is eliminated in the urine unchanged, while 64% of diphenhydramine is eliminated in the urine as metabolites. The elimination of dimenhydrinate has not been fully studied.
Volume of Distribution
The volume of distribution of dimenhydrinate is 3-4 L/kg.
DIMENHYDRINATE (ETHANOLAMINES): DURATION OF ACTION (HR) 4-6. /FROM TABLE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 609
H1 ANTAGONISTS ARE READILY ABSORBED FROM GI TRACT & PARENTERAL SITES OF ADMIN. FOLLOWING ORAL ADMIN, EFFECTS START WITHIN 15 TO 30 MIN, ARE FULLY DEVELOPED WITHIN 1 HR, & LAST ABOUT 3 TO 6 HR, ALTHOUGH SOME...ACT LONGER. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 607
Dimenhydrinate is a theoclate salt that separates into [diphenhydramine] and [8-chlorotheophylline]. diphenhydramine can either be N-glucuronidated by UGTs to diphenhydramine N-glucuronide or N-demethylated by CYP2D6, CYP1A2, CYP2C9, and CYP2C19 to N-desmethyldiphenhydramine. N-desmethyldiphenhydramine can be N-demethylated again by the same enzymes to N,N-didesmethyldiphenhydramine, which undergoes oxidative deamination to form diphenylmethoxyacetic acid.
EXTENSIVE STUDIES OF METABOLIC FATE OF ANTIHISTAMINES HAVE BEEN LIMITED TO A FEW COMPD. ... MAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 607
The plasma elimination half life of dimenhydrinate is 5-8 hours.
Dimenhydrinate is a theoclate salt that separates into [diphenhydramine] and [8-chlorotheophylline]. While the exact mechanism of action is unknown, diphenhydramine is theorized to reduce disturbances to equilibrium through antimuscarinic effects or histamine H1 antagonism. 8-chlorotheophylline may produce excitation through blocking adenosine receptors, reducing the drowsiness produced by diphenhydramine.
IT IS ESSENTIAL TO NOTE THAT NEITHER H1...BLOCKERS INHIBIT HISTAMINE RELEASE. ...EFFECTS OF HISTAMINE ANTAGONISTS...FACILITATE RELEASE. BENEFICIAL EFFECTS OF HISTAMINE ANTAGONISTS ARE THUS CONFINED TO ANTAGONISM OF RESPONSES TO HISTAMINE THAT IS RELEASED. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 605
DRUGS USED TO BLOCK HISTAMINE RECEPTORS FALL INTO THAT LARGE GROUP OF PHARMACOLOGICAL ANTAGONISTS THAT APPEAR TO ACT BY OCCUPYING "RECEPTIVE SITES" ON EFFECTOR CELL, TO EXCLUSION OF AGONIST MOLECULES, WITHOUT THEMSELVES INITIATING RESPONSE. TYPICALLY...COMPETITIVE & REVERSIBLE. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 603
...ANTIHISTAMINES EFFECTIVE IN MOTION SICKNESS ACT BY VIRTUE OF CENTRAL ANTAGONISM OF ACH... ACT BY BLOCKING EXCITATORY LABYRINTHINE IMPULSES @ CHOLINERGIC SYNAPSES IN REGION OF VESTIBULAR NUCLEI. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 606
...MOTION SICKNESS. ...STIMULATION OF VESTIBULAR APPARATUS...& THAT VESTIBULAR CEREBELLAR MIDBRAIN "INTEGRATIVE VOMITING CENTER" & MEDULLARY CHEMORECEPTIVE TRIGGER ZONE ARE SOMEHOW INVOLVED. /ANTIHISTAMINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 606
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Granulation
Controlled & Modified Release
Thickeners and Stabilizers
Taste Masking
Co-Processed Excipients
Film Formers & Plasticizers
Chewable & Orodispersible Aids
Lubricants & Glidants
Parenteral
Solubilizers
Topical
Empty Capsules
API Stability Enhancers
Emulsifying Agents
Vegetarian Capsules
Rheology Modifiers
Coloring Agents
Soft Gelatin
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Dimenhydrinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dimenhydrinate, including repackagers and relabelers. The FDA regulates Dimenhydrinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dimenhydrinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dimenhydrinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dimenhydrinate supplier is an individual or a company that provides Dimenhydrinate active pharmaceutical ingredient (API) or Dimenhydrinate finished formulations upon request. The Dimenhydrinate suppliers may include Dimenhydrinate API manufacturers, exporters, distributors and traders.
click here to find a list of Dimenhydrinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dimenhydrinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dimenhydrinate active pharmaceutical ingredient (API) in detail. Different forms of Dimenhydrinate DMFs exist exist since differing nations have different regulations, such as Dimenhydrinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dimenhydrinate DMF submitted to regulatory agencies in the US is known as a USDMF. Dimenhydrinate USDMF includes data on Dimenhydrinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dimenhydrinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dimenhydrinate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dimenhydrinate Drug Master File in Japan (Dimenhydrinate JDMF) empowers Dimenhydrinate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dimenhydrinate JDMF during the approval evaluation for pharmaceutical products. At the time of Dimenhydrinate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dimenhydrinate suppliers with JDMF on PharmaCompass.
A Dimenhydrinate CEP of the European Pharmacopoeia monograph is often referred to as a Dimenhydrinate Certificate of Suitability (COS). The purpose of a Dimenhydrinate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dimenhydrinate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dimenhydrinate to their clients by showing that a Dimenhydrinate CEP has been issued for it. The manufacturer submits a Dimenhydrinate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dimenhydrinate CEP holder for the record. Additionally, the data presented in the Dimenhydrinate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dimenhydrinate DMF.
A Dimenhydrinate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dimenhydrinate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dimenhydrinate suppliers with CEP (COS) on PharmaCompass.
A Dimenhydrinate written confirmation (Dimenhydrinate WC) is an official document issued by a regulatory agency to a Dimenhydrinate manufacturer, verifying that the manufacturing facility of a Dimenhydrinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dimenhydrinate APIs or Dimenhydrinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Dimenhydrinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Dimenhydrinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dimenhydrinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dimenhydrinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dimenhydrinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dimenhydrinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dimenhydrinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dimenhydrinate suppliers with NDC on PharmaCompass.
Dimenhydrinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dimenhydrinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dimenhydrinate GMP manufacturer or Dimenhydrinate GMP API supplier for your needs.
A Dimenhydrinate CoA (Certificate of Analysis) is a formal document that attests to Dimenhydrinate's compliance with Dimenhydrinate specifications and serves as a tool for batch-level quality control.
Dimenhydrinate CoA mostly includes findings from lab analyses of a specific batch. For each Dimenhydrinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dimenhydrinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dimenhydrinate EP), Dimenhydrinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dimenhydrinate USP).
LOOKING FOR A SUPPLIER?
